60 Degrees Pharmaceuticals (SCTP) Registration Filing summary

Company overview and business model

• Specialty pharmaceutical company focused on developing and commercializing therapies for infectious diseases, with a lead product approved for malaria prevention and a pipeline targeting vector-borne, fungal, and viral diseases.

• Business model leverages repositioning of existing molecules with established safety profiles to reduce development cost and risk.

• Commercial strategy includes expanding Arakoda (tafenoquine) sales for malaria and pursuing new indications such as babesiosis and fungal infections.

• Operates with a small, virtual management team and relies on partnerships with public and academic entities.

Financial performance and metrics

• 2024 product revenues were $607,574, up 140% from $253,573 in 2023, driven by increased U.S. sales and organic growth in the Lyme disease community.

• Gross margin improved to 36.7% in 2024 from -87.2% in 2023 due to higher sales volume and lower inventory write-downs.

• Operating loss was $9.7 million in 2024, up from $5.2 million in 2023, reflecting increased R&D and G&A expenses.

• Net loss attributed to the company was $7.95 million in 2024, compared to $3.77 million in 2023.

• Cash and cash equivalents at year-end 2024 were $1.66 million, with a going concern warning from auditors.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling stockholders; potential proceeds of up to $2.66 million if all warrants are exercised, to be used for general corporate purposes and working capital.

• Recent capital raises include $1.9 million from a January 2024 offering, $1.7 million from an ATM program, and $3.4 million from a September 2024 private placement.

• Ongoing need for additional capital to fund operations and clinical trials, with sufficient funds projected through August 2025 excluding new trial costs.